Developing novel immunotherapies for cancer with a focus on CD47 blockade

Trillium utilizes biologic- and small molecule-based approaches to enhance the ability of the patient’s own immune system to detect and destroy cancer cells. Our lead programs are directed against CD47, an immune checkpoint inhibitor that functions as a “do not eat” signal. We are also developing novel fluorine-based small molecules directed against other immuno-oncology targets in our discovery program.